CAS: 1037184-44-3; 4,7-Dichloro-3-Hydroxy-3-(2-(4-Methoxyphenyl)-2-Oxoethyl)Indolin-2-One

上下游产品

4,7-dichloroisatin 1-(4-methoxyphenyl)ethanone

📜4,7-二氯吲哚满二酮,对甲氧基苯乙酮置于二乙胺体系中,用 甲醇 用作溶剂,化学反应生成Yk 4-279; 4,7-二氯-1,3-二氢-3-羟基-3-[2-(4-甲氧基苯基)-2-氧代乙基]-2H-吲哚-2-酮
参考文献: Indoline Analogs And Uses Thereof[fr] Analogues D'Indoline Et Leurs Utilisations
标题: Indoline Analogs And Uses Thereof[fr] Analogues D'Indoline Et Leurs Utilisations
摘要:提供了作为ews-Fli1转录因子抑制剂的吲哚衍生物化合物.还提供了这些吲吲衍生物的药物组合物,合成方法,使用方法以及用于识别ews-Fli1致癌蛋白抑制剂的测定方法.

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.